Affigen develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain cancers such as leukemias or lymphomas. Founded in 2016, Affigen utilizes precision design to drive powerful immune responses against molecules unique to cancer, while minimizing the risk of damage to healthy tissues.
Scientific research over the last 30 years has shown the immense potential of this approach, but only recently has it become possible to produce this new class of commercially viable therapeutics that maximize both anti-tumor activity and safety in patients with critically unmet medical needs.
The Affigen team includes experts in immuno-oncology and mass-personalized biomolecular engineering with extensive experience in oncology, manufacturing, regulatory affairs, genomics, bioinformatics, and clinical program development. Affigen develops therapeutics with rapid clinical adoption in mind, and works in close collaboration with leading U.S. academic research centers.